Specific outcomes are associated with various factors representing the severity of the disease, including the peritoneal cancer index (PCI), the completeness of cytoreduction (CC), and tumor histopathology. Patients have been found to respond well to this treatment, with median overall survival (OS) rates increasing to between 20 and 63 months and 5-year OS rates of 23–52%. In this context, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been found to be successful for treating colorectal cancer accompanied by PM, and this combination, although initially developed for treating pseudomyxoma peritonei, is now accepted as a standard surgical treatment for all malignancies of the peritoneal surface regardless of their origin. Systemic treatment for PM has limited success, often only increasing the median survival from 12 to 16 months. If untreated, such patients typically do not live longer than a year. Peritoneal metastases (PM) usually present with relatively nonspecific symptoms and are thus often only detected at advanced stages thus, PM are associated with poor outcomes. Metastasis to the peritoneum and liver is common. Of these, between 20 and 25% of patients have advanced cancer, with the same numbers developing metastases after surgery. ConclusionsĬRS + HIPEC can improve the survival rate of patients with colorectal cancer peritoneal metastasisĬolorectal cancer is responsible for close to 10% of cancer diagnoses and deaths throughout the world, with about 2 million new diagnoses per year. The results showed that the OS of CRS + HIPEC group was higher than that of control group ( HR: 0.53, 95% CI: 0.38–0.73 P 0.05, indicating that there is no publication bias. The 3 randomized controlled studies were of high quality, and the quality scores of the 7 cohort studies were all 7 or above, indicating high quality. ResultsĪ total of 3200 patients were enrolled in the study, including 788 patients in the CRS and HIPEC groups and 2412 patients in the control group, of which 3 were randomized controlled trials and 7 were cohort studies. Ten studies were included in qualitative and quantitative analysis. The PubMed, Embase, Cochrane, Web of Knowledge, and databases were screened from inception of the review to March 11, 2022. This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The purpose of this study is to evaluate the impact of CRS + HIPEC on survival and provide reference for the treatment of patients with colorectal cancer peritoneal metastasis. A large body of evidence highlights the beneficial effects of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on survival, but to date, there is little consensus on the optimal treatment strategy for patients with colorectal cancer peritoneal metastasis. Peritoneal metastasis often occurs in patients with colorectal cancer peritoneal metastasis, and the prognosis is poor.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |